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Summary
Background: Cardiac biomarkers and echocardiog-
raphy for assessing right ventricular function are rec-
ommended to risk stratify patients with acute
non-massive pulmonary embolism (PE), but it re-
mains unclear if these tests are performed systemat-
ically in daily practice.
Design and methods: Overall, 587 patients with
acute non-massive PE from 18 hospitals were en-
rolled in the Swiss Venous Thromboembolism
Registry (SWIVTER): 178 (30%) neither had a bio-
marker test nor an echocardiographic evaluation,
196 (34%) had a biomarker test only, 47 (8%) had
an echocardiogram only and 166 (28%) had both
tests.
Results: Among the 409 (70%) patients with bio-
markers or echocardiography, 210 (51%) had at
least one positive test and 67 (16%) had positive
biomarkers and right ventricular dysfunction. The
ICU admission rates were 5.1% without vs. 5.6%
with testing (P= 0.78), and thrombolysis or embol-
ectomy were performed in 2.8% vs. 4.9%, respect-
ively (P= 0.25). In multivariate analysis, syncope
[odds ratio (OR): 3.49, 95% confidence interval
(CI): 1.20–10.15; P=0.022], tachycardia (OR:
2.31, 95% CI: 1.37–3.91; P=0.002) and increasing
age (OR: 1.02; 95% CI: 1.01–1.04; P<0.001) were
associated with testing of cardiac risk; outpatient
status at the time of PE diagnosis (OR: 2.24, 95%
CI: 1.49–3.36; P< 0.001), cancer (OR: 1.81, 95%
CI: 1.17–2.79; P= 0.008) and provoked PE (OR:
1.58, 95% CI: 1.05–2.40; P= 0.029) were associated
with its absence.
Conclusions: Although elderly patients and
those with clinically severe PE were more likely to
receive a biomarker test or an echocardiogram,
these tools were used in only two-thirds of the pa-
tients with acute non-massive PE and rarely in
combination.
! The Author 2012. Published by Oxford University Press on behalf of the Association of Physicians.
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Introduction
Annually, pulmonary embolism (PE) accounts for
more than 100000 deaths in the USA1 and 330000
deaths in Europe,2 with right ventricular (RV) dysfunc-
tion as the most common cause of early mortality.3
In PE patients who present with preserved systemic
pressure and without signs of cardiogenic shock,
common clinical signs of RV dysfunction include
tachycardia, hypoxia and distended jugular veins.
The electrocardiogram may reveal signs of RV
strain, including right bundle branch block, the
SI–QIII type or inverted T waves in the precordial
leads.4 However, the assessment of RV function is
often unreliable based on the initial clinical evalu-
ation. For risk stratification of hemodynamically
stable PE patients, current consensus guidelines of
the European Society of Cardiology5 and the
American Heart Association6 recommend routine as-
sessment of RV function by cardiac biomarkers and/
or echocardiography.
Although patients with normal levels of cardiac
biomarkers or with preserved RV function on echo-
cardiography have an excellent early prognosis,7,8
positive biomarker tests or RV dysfunction are
strong predictors of adverse clinical outcomes.9–12
In the Swiss Venous Thromboembolism Registry
(SWIVTER), cardiac troponin testing provided incre-
mental prognostic information on top of the initial
clinical evaluation with the simplified PE Severity
Index (sPESI).13 Current consensus guidelines from
the European Society of Cardiology5 and the
American Heart Association6 recommend the ad-
ministration of reperfusion therapy, including
thrombolysis, catheter intervention or surgical em-
bolectomy in selected PE patients at increased risk
of death.
This study was performed to investigate how fre-
quently cardiac risk stratification tests are being per-
formed in hemodynamically stable patients with
acute PE and to compare clinical characteristics
and treatment modalities between patients with
and without cardiac risk stratification.
Methods
Patients
Four Swiss academic and 14 non-academic acute
care hospitals representatively distributed over the
country enrolled 644 consecutive patients with
acute PE in the prospective SWIVTER between
January 2009 and May 2010. Inclusion criteria
were age518 years and objectively confirmed
acute PE. There were no exclusion criteria in
SWIVTER. Department chiefs of participating hos-
pitals were invited to participate in SWIVTER for
enrolling consecutive patients with acute PE.
Eligible patients were enrolled at the time of PE diag-
nosis and registered directly by treating physicians
or dedicated study personal at medical or surgical
wards or at the emergency department of participat-
ing hospitals. Patient informed consent was waived,
and anonymous data were entered by treating phys-
icians or dedicated study personal directly from the
patient chart into an electronic case report form. PE
diagnosis had to be objectively confirmed by
contrast-enhanced chest computed tomography,
ventilation perfusion scintigraphy or conventional
pulmonary angiography. For the present analysis,
we excluded 39 (6%) patients with massive PE,
defined as systolic systemic pressure of <90mm
Hg, and 18 (3%) patients treated on an outpatient
basis without follow-up data of whom one patient
had an increased sPESI. Overall, 587 (91%) patients
with acute non-massive PE were included in our
analysis. In accordance with local regulations, the
study was approved by the local ethics committees
of participating hospitals.
Data and definitions
Two study groups were formed: patients with car-
diac risk stratification and patients without cardiac
risk stratification. Cardiac risk stratification was
defined as the presence of a biomarker test result
or an echocardiographic evaluation for assessing
RV function within 24 h of PE diagnosis. SWIVTER
did not issue recommendations on the indications of
biomarker testing and echocardiography.
Biomarker testing was performed in the central la-
boratory of participating hospitals. Test results were
taken from laboratory slips. Accepted biomarker tests
included conventional troponin I (Beckman Coulter
TnI, cut-off: 0.09mg/l), conventional (Roche Elecsys
cTnT, cut-off: 0.1mg/l) or highly sensitive (Roche
Elecsys cTnT-hs, cut-off: 0.014mg/l) troponin T and
B-type natriuretic peptide (BNP, Alere Triage BNP,
cut-off: 100pg/ml). A positive biomarker test was
defined as a biomarker level above the mentioned
assay thresholds.
Standard transthoracic echocardiography was
performed and interpreted by a local cardiologist.
Data on RV function were taken from echocardio-
graphic reports. There was no central adjudication
of echocardiographic images in SWIVTER, but RV
dysfunction on echocardiography was predefined
and diagnosed from participating centers if at least
one of the following signs was present: RV dimen-
sion >30mm in the parasternal long axis, right-
to-left ventricular dimension ratio >0.9 in the
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apical four-chamber view, moderate or severe sys-
tolic RV dysfunction, tricuspid systolic velocity
>2.6m/s, septal flattening or paradoxical septal
motion.
Non-massive PE was defined as systemic blood
pressure of 590mm Hg. Provoked PE was defined
according to the guidelines of the American College
of Chest Physicians as PE associated with surgery,
hospitalization, immobilization for more than
3 days, estrogen therapy, pregnancy or prolonged
travel of >5 h, all within 30 days prior to PE diagno-
sis.14 An increased sPESI was defined as presence of
at least one of the following criteria: age >80 years,
systemic systolic pressure <100mmHg, heart rate
>110 beats/min, oxygen saturation <90%, cancer,
heart failure or chronic lung disease.15
A standardized electronic case report form was
used for the collection of anonymous data on pa-
tient demographics, hospital status at the time of PE
diagnosis, clinical presentation, thrombosis localiza-
tion and risk factors, cardiac risk stratification test
results, treatment and 30-day clinical outcomes
including mortality, symptomatic objectively con-
firmed recurrent PE and bleeding requiring medical
attention. Overall, 499 (85%) patients had com-
pleted 30-day follow-up, 76 (13%) had follow-up
data for a minimum of 15 days and 12 (2%) for
<15 days.
Statistical analysis
For comparison of clinical characteristics and treat-
ment modalities between patients with and without
cardiac risk stratification, we analyzed patient
demographics, acute and chronic comorbidities,
clinical markers of PE severity, anticoagulation
therapy and reperfusion therapy, including thromb-
olysis, catheter interventions and surgical embolec-
tomy. For these analyses, group comparisons for
continuous variables with a normal distribution
were performed by t-test, for continuous variables
with a skewed distribution by a rank sum test and
for discrete variables by the chi square or Fisher’s
exact test.
Univariate logistic regression analysis reporting
odds ratios (OR) with 95% confidence intervals
(CI) was conducted to identify clinical factors asso-
ciated with cardiac risk stratification. Subsequently,
multivariate logistic regression analysis was per-
formed to identify clinical factors associated with
cardiac risk stratification. Univariate predictors
with a P value < 0.05 were entered in the regression
model, and a backward elimination procedure was
used to stepwise discard variables without signifi-
cance. All reported P values are two tailed. Data
were analyzed using STATA 10 software
(STATACorp LP, College Station, TX, USA).
Results
Patient characteristics
Overall, 178 (30%) patients neither had a cardiac
biomarker test nor an echocardiographic evaluation,
196 (34%) had a biomarker test only, 47 (8%) had
an echocardiogram only and 166 (28%) had both
tests. Among the 409 (70%) patients with bio-
markers or echocardiography, 210 (51%) had at
least one positive test and 67 (16%) had positive
biomarkers and RV dysfunction on echocardiogram
(Figure 1).
In comparison to patients with cardiac risk strati-
fication, patients without cardiac risk stratification
were younger, more often outpatient at the time of
PE diagnosis and more frequently had provoked or
cancer-associated PE (Table 1). Patients without
cardiac risk stratification less frequently had hyp-
oxia, tachycardia, syncope, embolism of the pul-
monary main stem or the main pulmonary arteries,
right heart strain on electrocardiography and an
increased sPESI than patients with cardiac risk
stratification.
Overall, 264 (45%) patients were treated in aca-
demic and 323 (55%) in non-academic centers.
There was no difference in the use of cardiac risk
stratification between academic vs. non-academic
centers (69% vs. 70%; P=0.73). Among patients
with cardiac risk stratification, a positive biomarker
test or RV dysfunction was more often present in
patients from non-academic vs. academic centers
(56% vs. 46%; P= 0.038). There was no difference
in the proportion of patients with an increased sPESI
(65% vs. 69%; P=0.33) and with main stem or main
pulmonary artery embolism (34% vs. 33%; P= 0.78)
between non-academic and academic centers.
Treatment of VTE
In comparison to patients with cardiac risk stratifica-
tion, patients without cardiac risk stratification less
often were treated on an inpatient basis and less fre-
quently received systemic thrombolysis (Table 1).
However, any reperfusion therapy, including sys-
temic thrombolysis, catheter intervention or surgical
embolectomy, was similarly often used in patients
with and without cardiac risk stratification. The ICU
admission rate was also similar in patients with vs.
without cardiac risk stratification.
Among the 166 patients with biomarker testing
and echocardiography, the hospitalization rates
were 100% in patients with positive biomarkers
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plus RV dysfunction and 96% in patients without
any positive test result (P= 0.08); the ICU admission
rates were similar (4.5% vs. 4.4%; P=0.99), and
there was more frequent use of reperfusion therapy
(14.9% vs. 2.2%; P=0.027), respectively.
Patients from academic centers were less often
hospitalized (86% vs. 92%; P=0.010), more fre-
quently received reperfusion therapy (7.2% vs.
1.9%; P=0.001) and more often were admitted to
the ICU (9% vs. 3%; P= 0.002) than those from
non-academic centers.
The overall rate of cumulative 30-day mortality
was 3.2%, the combined rate of 30-day mortality
or recurrent PE 4.4% and the rate of 30-day bleeding
requiring medical attention 4.6%. There was no sig-
nificant difference in the combined rate of 30-day
mortality or recurrent PE between academic vs.
non-academic centers (5.9% vs. 3.2%; P=0.13).
Predictors of the use of cardiac risk
stratification
In multivariate analysis, syncope, tachycardia and
increasing age were associated with testing of car-
diac risk; outpatient status at the time of PE diagno-
sis, cancer and provoked PE were associated with its
absence (Table 2).
Discussion
In SWIVTER, cardiac biomarkers and echocardiog-
raphy were used in only two-thirds of the patients
with acute non-massive PE and rarely in combin-
ation. Elderly patients and those with clinically
severe PE were more likely to receive a biomarker
test or an echocardiogram.
Cardiac risk stratification was associated with a
higher proportion of inpatient treatment and an
increased use of systemic thrombolysis as compared
to patients without cardiac risk assessment. However,
only a minority of patients (7%) with at least one posi-
tive test result received reperfusion therapy, suggest-
ing that cardiac risk stratification test results were
rarely used to guide management decisions. These
findings may be explained by the fact that to date
no convincing outcome data are available to support
the use of reperfusion therapy for hemodynamically
stable PE patients with biochemical or echocardio-
graphic evidence of RV dysfunction.
Our study identified several factors associated with
absent testing of cardiac risk. Patients without car-
diac risk stratification were younger and more often
outpatient at the time of diagnosis and had clinically
and anatomically less severe PE. In contrast, other
patients without cardiac risk stratification had import-
ant comorbidities as reflected by a greater proportion
of patients with an increased sPESI as compared to
patients with cardiac risk stratification. Obviously,
physicians often abstained from ordering biomarker
tests or echocardiography in two distinct risk scen-
arios: prognosis was likely estimated as being poor in
the presence of cancer and other severe comorbid-
ities, and it was estimated as being favorable in case
of younger age or clinically less severe PE.
Figure 1. Biomarker testing and echocardiographic results with rates of reperfusion therapy. biomarker +, positive cardiac
biomarker; biomarker –, negative cardiac biomarker; echo +, RV dysfunction on echocardiography; echo –, no RV dys-
function on echocardiography; no echo, echocardiography not available.
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In our study, patient characteristics, comorbidities
and clinical findings were consistent with other stu-
dies on patients with acute non-massive PE.16,17 The
proportion of patients with an increased sPESI in our
study (66%) and in the validation study (69%) was
similar.15 Overall, 90% of the patients were mana-
ged in-hospital in our study. However, this propor-
tion will possibly decline in the future because
outpatient management is feasible and safe
according to a recent randomized trial on outpatient
management of low-risk PE patients.18
One strength of our study is the prospective
enrollment of consecutive patients with acute non-
massive PE and the systematic collection of informa-
tion on biomarker test results, echocardiographic
evaluation and medical management. To the best
of our knowledge, SWIVTER is the first study to
evaluate the use of cardiac risk stratification in
Table 1 Demographics, comorbidities, clinical findings and VTE therapy
Total (N= 587) Cardiac risk
stratification
(N= 409)
No cardiac
risk stratification
(N= 178)
P
Demographics
Age, mean years SD 65 16 67 16 61 18 <0.001
Age >80 years, n (%) 105 (17.9) 81 (19.8) 24 (13.5) 0.07
Women, n (%) 273 (46.5) 198 (48.4) 75 (42.1) 0.16
Inpatient at the time of diagnosis, n (%) 301 (48.7) 188 (54.0) 113 (36.5) <0.001
Duration of hospital stay, median days (IQR) 10 (6–19) 10 (6–17) 13 (7–26) 0.017
Comorbidities
Cancer, n (%) 149 (25.4) 92 (22.5) 57 (32.0) 0.015
Prior thromboembolism, n (%) 143 (24.4) 98 (24.0) 45 (25.3) 0.73
Bed rest for >3 days within 30 days, n (%) 99 (16.9) 60 (14.7) 39 (21.9) 0.031
Chronic lung disease, n (%) 85 (14.5) 53 (13.0) 32 (18.0) 0.11
Obesity, n (%) 84 (14.3) 64 (15.7) 20 (11.2) 0.16
Surgery within 30 days, n (%) 74 (12.6) 49 (12.0) 25 (14.0) 0.49
Acute respiratory failure, n (%) 47 (8.0) 35 (8.6) 12 (6.7) 0.46
Congestive heart failure, n (%) 45 (7.7) 36 (8.8) 9 (5.1) 0.12
Ongoing chemotherapy, n (%) 41 (7.0) 23 (5.6) 18 (10.1) 0.050
ICU admission, n (%) 32 (5.5) 23 (5.6) 9 (5.1) 0.78
Prior bleeding requiring medical attention
within 30 days, n (%)
29 (4.9) 17 (4.2) 12 (6.7) 0.18
Thrombocytopenia, n (%) 17 (2.9) 9 (2.2) 8 (4.5) 0.13
Clinical findings
Dyspnea, n (%) 483/584 (82.7) 351/408 (86.0) 132/176 (75.0) 0.001
Right heart strain on ECG, n (%) 204/448 (45.5) 177/363 (48.8) 27/85 (31.8) 0.005
Provoked PE, n (%) 218 (37.1) 138 (33.7) 80 (44.9) 0.010
Thrombosis of main stem or main
pulmonary arteries, n (%)
197 (33.6) 151 (36.9) 46 (25.8) 0.009
Oxygen saturation in room air <90%, n (%) 146/526 (27.8) 112/364 (30.8) 34/162 (21.0) 0.021
Heart rate 5110 beats/min, n (%) 130/563 (23.1) 107/396 (27.0) 23/167 (13.8) 0.001
Syncope, n (%) 44/584 (7.5) 40/408 (9.8) 4/176 (2.3) 0.002
Increased sPESI, n (%) 390 (66.4) 285 (69.7) 105 (59.0) 0.012
Therapy
Inpatient therapy, n (%) 524 (89.3) 381 (93.2) 143 (80.3) <0.001
Reperfusion therapy,a n (%) 25 (4.3) 20 (4.9) 5 (2.8) 0.25
Systemic thrombolysis, n (%) 13 (2.2) 13 (3.2) 0 (0.0) 0.016
Catheter therapy, n (%) 8 (1.4) 6 (1.5) 2 (1.1) 0.74
Surgical thrombectomy, n (%) 7 (1.2) 4 (1.0) 3 (1.7) 0.47
Inferior vena cava filter, n (%) 14 (2.4) 10 (2.4) 4 (2.3) 0.89
Planned duration of anticoagulation
43 months, n (%) 38 (6.5) 23 (5.6) 15 (8.4) 0.20
>3–12 months, n (%) 374 (63.7) 259 (63.3) 115 (64.6) 0.77
>12 months or indefinite, n (%) 175 (29.8) 127 (31.1) 48 (27.0) 0.32
aSome patients had a combination of systemic thrombolysis, catheter therapy or surgical thrombectomy
VTE, venous thromboembolism; ICU, intensive care unit; sPESI, simplified Pulmonary Embolism Severity Index.
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routine clinical practice. One study limitation is that
there was no central adjudication of echocardio-
graphic test results, and quality of echocardiography
and its interpretation may have varied between cen-
ters. As timing of cardiac risk stratification tests and
management decisions was not captured, it was not
possible to investigate the effect of risk stratification
test results on management decisions, particularly
on outpatient versus inpatient management. The
large ongoing PE International Thrombolysis
(PEITHO, ClinicalTrials.gov Identifier:
NCT00639743) trial on patients with biochemical
and imaging evidence of RV dysfunction will help
answering the question whether there is a role for
routine cardiac risk stratification followed by reper-
fusion therapy in this setting.
In summary, biochemical or imaging tests indicat-
ing RV dysfunction were used in only two-thirds of
the patients with acute non-massive PE, and such
testing was not associated with more aggressive
management, including admission to the ICU or ad-
ministration of reperfusion treatment.
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